Epistat Therapeutics

Preventing the most common cancers in the world.

Squamous and basal cell skin cancers affect millions of high-risk patients, who face repeated surgery and scarring. There is no approved medicine to prevent them. We are building one.

For investors → For patients →

The problem

Skin cancer is the most common cancer in humans, and there is no medicine to prevent it.

The platform

A proprietary human-tissue platform that finds medicines to keep skin healthy.

The opportunity

A multi-billion-pound global market with no incumbent.

Read the investor story →

What we do

A platform to discover medicines that prevent skin cancer before it starts.

Epistat pairs a proprietary human-tissue screening platform with a dermatology-led team to build a pipeline of preventive treatments for the people at highest risk of skin cancer.

#1
most common cancer in humans
>6M
new non-melanoma skin cancers a year worldwide
10-20M
people at high risk worldwide
0
approved medicines to prevent it

Building the first preventive medicines for skin cancer.

We are raising investment and building our advisory board. If you would like to invest, partner or advise, we would be glad to hear from you.

For investors Get in touch

Part of the King's College London Spinout Accelerator King's College London